SAN DIEGO, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP announces that a class action lawsuit has commenced on behalf of investors of MacroGenics, Inc. ("MacroGenics") (NASDAQ: MGNX). If you incurred significant losses and want to act as the lead plaintiff in the MacroGenics class action lawsuit or determine if you are eligible to receive a potential recovery of your losses, please submit your details here: SUBMIT YOUR INFORMATION NOW CLASS PERIOD: March 7, 2024 to May 9 ...

NEW YORK, Aug. 2, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in MacroGenics, Inc. ("MacroGenics" or the "Company") (NASDAQ: MGNX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of MacroGenics investors who were adversely affected by alleged securities fraud between March 7, 2024 and May 9, 2024. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/macrogenics-inc-lawsuit-submi ...

NEW YORK, Aug. 1, 2024 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of stock or sellers of puts of MacroGenics, Inc. (NASDAQ: MGNX) between March 7, 2024 and May 9, 2024, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 24, 2024. To join the MacroGenics class action, go to https://rosenleg ...

RADNOR, Pa., Aug. 01, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the District of Maryland against MacroGenics, Inc. ("MacroGenics") (NASDAQ: MGNX) on behalf of investors who purchased MacroGenics stock or sold MacroGenics puts between March 7, 2024 to May 9, 2024, inclusive (the "Class Period") The lead plaintiff deadline is September 24, 2024. CONTA ...

NEW ORLEANS, July 31, 2024 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until September 24, 2024 to file lead plaintiff applications in a securities class action lawsuit against MacroGenics, Inc. (or the "Company") (NasdaqGS: MGNX), if they purchased the Company's shares or sold the Company's puts between March 7, 2024 to May 9, 2024, inclusive (the "Class Period"). This action is pending in the United States District Court for the District of Mar ...

MacroGenics Inc. MGNX announced on Tuesday that it reviewed data accumulated from the TAMARACK Phase 2 study of vobramitamab duocarmazine (vobra duo). In May, when the company released interim data from the trial, MacroGenics reported five deaths (fatal outcome) during the trial. After reviewing, MacroGenics agreed with the study's Independent Data Monitoring Committee's recommendation to discontinue the treatment for the remaining metastatic castration-resistant prostate cancer (mCRPC) study participants w ...

NEW YORK, July 31, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in MacroGenics, Inc. ("MacroGenics" or the "Company") (NASDAQ: MGNX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of MacroGenics investors who were adversely affected by alleged securities fraud between March 7, 2024 and May 9, 2024. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/macrogenics-inc-lawsuit- ...

Macrogenics (NASDAQ:MGNX) stock is dropping on Wednesday as the biopharmaceutical company prepares to discontinue a clinical trial of vobramitamab duocarmazine. How This Affects MGNX Stock On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines. Scott Koenig, M.D., Ph.D., president and CEO of MacroGeni ...

SAN DIEGO, July 30, 2024 (GLOBE NEWSWIRE) -- Robbins LLP informs investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired MacroGenics, Inc. (NASDAQ: MGNX) common stock between March 7, 2024 and May 9, 2024. MacroGenics is a biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Allegations: Robbins LLP is Investigatin ...

Core Insights - MacroGenics announced five fatal outcomes in its TAMARACK Phase 2 study of vobramitamab duocarmazine for metastatic castration-resistant prostate cancer, leading to a significant decline in share price [1] - The share price dropped by $11.36, or approximately 77.4%, from $14.67 on May 9, 2024, to close at $3.31 on May 10, 2024 [1] Legal Actions - A class action lawsuit has been filed against MacroGenics in the United States District Court for the District of Maryland, representing all individuals and entities who acquired MacroGenics securities between March 7, 2024, and May 9, 2024 [4] - Investors have until September 24, 2024, to apply to be appointed as lead plaintiff in the lawsuit [4] - The lawsuit alleges that MacroGenics made material misrepresentations by providing overly positive statements while concealing adverse facts related to early interim safety data from the TAMARACK Phase 2 study [6]